限制性股票激励计划
Search documents
桐昆集团股份有限公司第九届董事会第二十一次会议决议公告
Shang Hai Zheng Quan Bao· 2025-11-21 19:36
登录新浪财经APP 搜索【信披】查看更多考评等级 股票代码:601233 股票简称:桐昆股份 公告编号:2025-068 桐昆集团股份有限公司 第九届董事会第二十一次会议决议公告 本公司及董事会全体成员保证本公告不存在任何虚假记载、误导性陈述或重大遗漏,并对其内容的真实 性、准确性、完整性承担法律责任。 桐昆集团股份有限公司(以下简称"桐昆股份"或"公司")第九届董事会第二十一次会议通知于2025年11 月11日以书面或电子邮件、电话等方式发出,会议于2025年11月21日在公司总部会议室以现场表决和通 讯表决相结合的方式召开,会议应到董事十一名,实到董事十一名。会议由董事长陈蕾女士主持,本次 会议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、法规的规定。经过有效表决,会 议一致通过如下决议: 一、审议并通过《关于选举代表公司执行公司事务的董事的议案》。 会议选举董事长陈蕾女士为代表公司执行公司事务的董事。根据修订后的《公司章程》第八条"董事长 为代表公司执行公司事务的董事,为公司的法定代表人",本次选举后,公司法定代表人未发生变更。 表决结果:赞成11票,反对0票,弃权0票。 二、审议并通过《关 ...
龙迅半导体(合肥)股份有限公司
Xin Lang Cai Jing· 2025-11-21 18:48
Group 1 - The company is preparing for an H-share issuance and listing, which involves various costs including underwriting fees, legal fees, and other related expenses [1] - The board of directors has been authorized to select professional intermediaries for the issuance, including sponsors, underwriters, and legal advisors [2][3] - The underwriting method will be determined based on market conditions and regulatory approvals [3] Group 2 - The company plans to issue H-shares to eligible investors in Hong Kong and other regions, transitioning to a dual listing on both A-share and H-share markets [7] - The board has proposed that the validity period for the issuance resolution be set at 24 months, extendable if regulatory approvals are obtained within this timeframe [10][29] - The company will use the funds raised for R&D, product expansion, market development, and general corporate purposes, with adjustments allowed based on actual needs [32][33] Group 3 - The company has appointed Ernst & Young as the auditor for the H-share issuance and listing [40] - The board has confirmed the roles of directors post-issuance, including executive and independent directors [43] - The company will apply for registration as a non-Hong Kong company in accordance with Hong Kong regulations [46][47] Group 4 - The company will purchase directors and officers liability insurance and prospectus liability insurance to enhance risk management [52][53] - The company has proposed amendments to its articles of association and related rules to align with the H-share issuance [54][55]
南京医药股份有限公司关于公司及子公司继续使用部分暂时闲置募集资金进行现金管理的公告
Shang Hai Zheng Quan Bao· 2025-11-21 18:33
Core Viewpoint - The company plans to continue using up to RMB 500 million of temporarily idle raised funds for cash management, focusing on low-risk, high-liquidity investment products to enhance fund utilization efficiency and shareholder returns [2][18][49]. Fundraising Basic Situation - The company raised a total of RMB 1,081.49 million through the issuance of convertible bonds, with a net amount of RMB 1,069.04 million after deducting issuance costs [3]. - The funds have been deposited in a dedicated account for regulatory management to protect investor interests [3]. Fund Usage and Balance - As of June 30, 2025, the balance of the raised funds in the dedicated account was RMB 124.10 million [5]. - The company anticipates that some of the raised funds may remain idle for a certain period due to project progress [7]. Previous Cash Management Situation - In January 2025, the company approved the use of up to RMB 700 million of temporarily idle funds for cash management, investing in low-risk financial products [8]. - By October 2025, the company had utilized RMB 455 million for cash management, including structured deposits and large-denomination certificates of deposit [8]. Proposed Cash Management - The company aims to use up to RMB 500 million of temporarily idle funds for cash management to improve efficiency and reduce financial costs [9][10]. - The investment products will include high-safety, high-liquidity, and capital-protected financial products, with a maximum investment period of 12 months [11][12]. Approval Process - The board of directors held a temporary meeting on November 20-21, 2025, to approve the cash management proposal, which does not require shareholder meeting approval [18][49]. Impact on Daily Operations - The proposed cash management will not affect the normal operation of the company or the progress of fundraising projects, and it is expected to enhance overall performance and shareholder returns [17].
吉宏股份:关于完成工商变更登记的公告
Zheng Quan Ri Bao Zhi Sheng· 2025-11-21 15:20
Core Points - Company announced the convening of the 29th meeting of the fifth board of directors and the first extraordinary general meeting of shareholders in 2025 to discuss several key proposals [1] - The company plans to repurchase and cancel 2,274,000 shares of restricted stock from the 2023 incentive plan due to unmet performance targets and the departure of seven incentive recipients [1] - The company will abolish the supervisory board, transferring its functions to the audit committee of the fifth board of directors, and has made corresponding amendments to its articles of association [1] - The company has completed the business registration change and obtained a new business license from the Xiamen Market Supervision Administration [1]
华荣科技股份有限公司关于2023年限制性股票激励计划第二个解除限售期解除限售条件成就的公告
Shang Hai Zheng Quan Bao· 2025-11-20 19:19
Core Viewpoint - The announcement details the achievement of conditions for the second unlock period of the 2023 restricted stock incentive plan of Huaron Technology Co., Ltd, allowing 212 individuals to unlock a total of 1.9785 million shares, representing approximately 0.59% of the company's total shares [2][8]. Summary by Sections Incentive Plan Overview - The second unlock period for the restricted stock incentive plan is approaching, with 212 eligible individuals and a total of 1.9785 million shares available for unlocking, which is about 0.59% of the total shares outstanding [2][8]. Decision-Making Process - The decision-making process for the incentive plan involved multiple meetings of the board and supervisory committee, with independent opinions provided by independent directors [3][4][5]. Unlock Conditions - The conditions for unlocking the restricted stocks have been met, and the board has confirmed that the necessary performance indicators and other criteria have been achieved [7][8]. Legal Compliance - The necessary procedures for the unlock have been followed, complying with relevant laws and regulations, and the company will fulfill its disclosure obligations as required [8][9].
普源精电科技股份有限公司2024年限制性股票激励计划第一类限制性股票回购注销的实施公告
Shang Hai Zheng Quan Bao· 2025-11-20 19:09
Core Viewpoint - The company is implementing a buyback and cancellation of restricted stock due to not meeting performance targets for the 2024 stock incentive plan, alongside factors such as employee departures and individual performance issues [2][5]. Group 1: Buyback and Cancellation Details - The company plans to repurchase and cancel a total of 229,613 shares of the first category of restricted stock held by 76 incentive recipients [2][3]. - The buyback price for the first category of restricted stock is set at 17.63 yuan per share for partners and 19.48 yuan per share for other recipients [3]. - The decision was approved in meetings held on August 8, 2025, by the company's board and supervisory committee [3]. Group 2: Reasons for Buyback - The company achieved a 15.70% year-on-year increase in revenue for 2024, meeting the trigger for performance assessment but not the target value [5]. - A total of 130,589 shares are to be repurchased due to 12 incentive recipients leaving the company, with the remaining shares being repurchased due to performance issues [5][6]. - Nine recipients received an "A-" performance rating, allowing only 60% of their shares to be released from restrictions, leading to further repurchases [6]. Group 3: Impact on Share Structure - Following the buyback, the total share capital will decrease from 194,104,030 shares to 193,874,417 shares [6]. - The remaining first category of restricted stock in the 2024 incentive plan will total 259,776 shares after the buyback [6]. Group 4: Compliance and Legal Opinions - The company has followed necessary procedures and legal requirements for the buyback and cancellation, ensuring no harm to the rights of incentive recipients or creditors [7][8]. - The law firm involved confirmed that the buyback complies with relevant regulations and that the company must continue to fulfill disclosure obligations regarding the reduction of registered capital [8].
武汉达梦数据库股份有限公司2025年第五次临时股东会决议公告
Shang Hai Zheng Quan Bao· 2025-11-20 18:47
Core Points - The company held its fifth extraordinary general meeting of shareholders on November 20, 2025, with no resolutions being rejected [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a combination of on-site and online voting [2][3] - All resolutions related to the 2025 Restricted Stock Incentive Plan were approved by more than two-thirds of the voting rights held by attending shareholders [5] Meeting Details - The meeting took place at the company's database industrial base in Wuhan, specifically in conference room 1810 on the 18th floor of Building 2 [2] - A total of 9 out of 11 current directors attended the meeting, along with all 3 supervisors and the board secretary [3] - The meeting was witnessed by lawyers from Guohao Law Firm, confirming the legality and validity of the meeting procedures and resolutions [5] Resolutions Passed - The following resolutions were approved: 1. The draft of the 2025 Restricted Stock Incentive Plan and its summary [4] 2. The management measures for the implementation assessment of the 2025 Restricted Stock Incentive Plan [5] 3. Authorization for the board of directors to handle matters related to the 2025 Restricted Stock Incentive Plan [5] Insider Trading Self-Examination - The company conducted a self-examination regarding insider trading by individuals aware of the 2025 Restricted Stock Incentive Plan prior to its public announcement [6][7] - During the self-examination period from April 28, 2025, to October 27, 2025, 9 individuals engaged in trading company stock [8] - Among these, 4 individuals traded after being aware of the incentive plan, but one claimed the trades were conducted by a family member without their knowledge [9] - The other 3 individuals, who were also proposed incentive recipients, stated they had limited knowledge of the plan's specifics and voluntarily opted out of participation [9] - The remaining 5 individuals traded before being aware of the incentive plan, confirming their trades were based on independent judgment [10] Conclusion of Self-Examination - The company confirmed that no insider information was leaked prior to the public announcement of the incentive plan, and no insider trading was detected among the relevant parties [12]
卧龙电气驱动集团股份有限公司九届二十一次临时董事会决议公告
Shang Hai Zheng Quan Bao· 2025-11-20 18:37
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:600580 证券简称:卧龙电驱公告编号:临2025-083 卧龙电气驱动集团股份有限公司 九届二十一次临时董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 卧龙电气驱动集团股份有限公司(以下简称"公司"或"卧龙电驱")九届二十一次临时董事会会议于2025 年11月19日以现场结合通讯表决方式召开。本次会议的会议通知和材料已于2025年11月16日分别以专人 送达、电子邮件或传真等方式发出。公司现有董事9人,参会董事9人,其中独立董事赵荣祥、张志铭、 邓春华以通讯方式参加,公司高级管理人员列席了会议。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定,表决 形成的决议合法、有效。 二、董事会会议审议情况 (一)审议通过《关于调整2025年限制性股票激励计划首次授予激励对象名单的议案》 (二)审议通过《关于向2025年限制性股票激励计划激励对象首次授予限制性股票的议案》 根据《上市公司股权激励管理 ...
江苏天奈科技股份有限公司关于2022年限制性股票激励计划预留授予部分第三个归属期归属结果暨股份上市的公告
Shang Hai Zheng Quan Bao· 2025-11-20 18:22
证券代码:688116 证券简称:天奈科技 公告编号:2025-085 转债代码:118005 债券简称:天奈转债 江苏天奈科技股份有限公司 关于2022年限制性股票激励计划预留授予部分 第三个归属期归属结果暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 登录新浪财经APP 搜索【信披】查看更多考评等级 ● 本次股票上市类型为股权激励股份;股票认购方式为网下,上市股数为15,895股。 本次股票上市流通总数为15,895股。 ● 本次股票上市流通日期为2025年11月25日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务 规则的规定,江苏天奈科技股份有限公司(以下简称"公司")收到中国证券登记结算有限责任公司上海 分公司于2025年11月19日出具的《证券变更登记证明》,公司已完成2022年限制性股票激励计划(以下 简称"2022年激励计划")预留授予部分第三个归属期的股份登记工作。现将有关情况公告如下: 一、激励计划已履行的决策程序和信息披露 ...
海泰新光(688677):Q3业绩加速上行,发布新一轮员工激励计划:海泰新光(688677):2025年三季报点评
Huachuang Securities· 2025-11-20 13:43
Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 57 yuan [4][8]. Core Insights - The company reported a significant increase in performance for Q3 2025, with total revenue reaching 448 million yuan, a year-on-year growth of 40.47%, and a net profit attributable to shareholders of 136 million yuan, also up by 40.03% [2][4]. - The growth in Q3 2025 was particularly strong, with revenue of 182 million yuan, representing an 85.26% increase year-on-year, and a net profit of 62 million yuan, which is a 130.72% increase [2][4]. - The company has launched a new employee incentive plan, granting 1 million restricted shares at a price of 25 yuan per share, focusing on employees related to overseas business [4][8]. Financial Performance Summary - For the first three quarters of 2025, the company's medical endoscope and optical businesses drove revenue growth, with the endoscope business alone seeing a 100% increase in Q3 [4][8]. - The after-sales service revenue also grew significantly, reaching 60 million yuan, an 80% increase year-on-year, with international after-sales contributing 53 million yuan [4][8]. - The gross profit margin remained stable, supported by the increase in sales volume and effective coordination between domestic and overseas production [4][8]. Financial Projections - The company forecasts total revenue of 601 million yuan for 2025, with a year-on-year growth rate of 35.8%, and net profit of 184 million yuan, reflecting a growth rate of 36.1% [4][9]. - Earnings per share (EPS) are projected to be 1.54 yuan in 2025, with corresponding price-to-earnings (P/E) ratios of 30, 24, and 20 for the years 2025, 2026, and 2027 respectively [4][9].